<?xml version='1.0' encoding='utf-8'?>
<document id="30472266"><sentence text="Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients."><entity charOffset="20-30" id="DDI-PubMed.30472266.s1.e0" text="Bortezomib" /><entity charOffset="35-48" id="DDI-PubMed.30472266.s1.e1" text="Dexamethasone" /><pair ddi="false" e1="DDI-PubMed.30472266.s1.e0" e2="DDI-PubMed.30472266.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30472266.s1.e0" e2="DDI-PubMed.30472266.s1.e1" /></sentence><sentence text="Osteolytic bone disease is one of the most debilitating manifestations of multiple myeloma (MM)" /><sentence text=" Bortezomib is a proteasome inhibitor that shows both anticancer and bone anabolic properties and is being evaluated for its positive effects in MM patients with skeletal complications"><entity charOffset="1-11" id="DDI-PubMed.30472266.s3.e0" text="Bortezomib" /></sentence><sentence text=" Dexamethasone is a potent corticosteroid that is often given in combination with bortezomib for its antineoplastic effects; however, bone loss and osteoporosis are major adverse effects of long-term steroid-based therapies"><entity charOffset="1-14" id="DDI-PubMed.30472266.s4.e0" text="Dexamethasone" /><entity charOffset="27-41" id="DDI-PubMed.30472266.s4.e1" text="corticosteroid" /><entity charOffset="82-92" id="DDI-PubMed.30472266.s4.e2" text="bortezomib" /><entity charOffset="200-207" id="DDI-PubMed.30472266.s4.e3" text="steroid" /><pair ddi="false" e1="DDI-PubMed.30472266.s4.e0" e2="DDI-PubMed.30472266.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30472266.s4.e0" e2="DDI-PubMed.30472266.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30472266.s4.e0" e2="DDI-PubMed.30472266.s4.e2" /><pair ddi="true" e1="DDI-PubMed.30472266.s4.e0" e2="DDI-PubMed.30472266.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30472266.s4.e1" e2="DDI-PubMed.30472266.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30472266.s4.e1" e2="DDI-PubMed.30472266.s4.e2" /><pair ddi="true" e1="DDI-PubMed.30472266.s4.e1" e2="DDI-PubMed.30472266.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30472266.s4.e2" e2="DDI-PubMed.30472266.s4.e2" /><pair ddi="true" e1="DDI-PubMed.30472266.s4.e2" e2="DDI-PubMed.30472266.s4.e3" /></sentence><sentence text=" In this study, a small systems pharmacological model was developed to integrate the bone anabolic effects of bortezomib with the osteolytic activity of dexamethasone in MM patients with bone disease"><entity charOffset="110-120" id="DDI-PubMed.30472266.s5.e0" text="bortezomib" /><entity charOffset="153-166" id="DDI-PubMed.30472266.s5.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.30472266.s5.e0" e2="DDI-PubMed.30472266.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30472266.s5.e0" e2="DDI-PubMed.30472266.s5.e1" /></sentence><sentence text=" The final model parameters were all estimated with good precision" /><sentence text=" The interaction model is based on codifying multiple regulatory mechanisms of drug action and provides a platform for probing optimized bortezomib and dexamethasone combination dosing regimens to minimize skeletal side effects during myeloma therapy"><entity charOffset="137-147" id="DDI-PubMed.30472266.s7.e0" text="bortezomib" /><entity charOffset="152-165" id="DDI-PubMed.30472266.s7.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.30472266.s7.e0" e2="DDI-PubMed.30472266.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30472266.s7.e0" e2="DDI-PubMed.30472266.s7.e1" /></sentence><sentence text="" /></document>